Getting your player ready...
The Food and Drug Administration has approved a new Pfizer drug for a subset of lung cancer patients with a particular genetic mutation. The twice-a-day pill, called Xalkori, is part of a new wave of personalized medications that fight disease by targeting specific genes found in certain patients. Last week, the FDA approved another drug that uses similar gene-targeting technology to treat two rare forms of lymph-node cancer.
